Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 45, 2507-2511, June 1, 1985]
© 1985 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellnier, D. A.
Right arrow Articles by Lin, C.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellnier, D. A.
Right arrow Articles by Lin, C.-W.

Photosensitization and Split-Dose Recovery in Cultured Human Urinary Bladder Carcinoma Cells Containing Nonexchangeable Hematoporphyrin Derivative1

David A. Bellnier2 and Chi-Wei Lin

Urology Service, Massachusetts General Hospital, and Department of Surgery, Harvard Medical School, Boston, Massachusetts 02114

The photosensitization and survival recovery of cultured EJ human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative (HPD) were studied. Cultures were incubated at 37°C in growth medium supplemented with HPD (50 µg/ml) and 5% fetal bovine serum for 12 h followed by incubation in HPD-free medium containing 5% fetal bovine serum for 9 or 18 h. The levels of porphyrin remaining in the cells (termed the "nonexchangeable" intracellular porphyrin component) were not significantly different at these times, and as a result sensitivities to broad-band red light (>580 nm) were also identical. Shouldered survival curves were obtained in each case, indicating the ability to accumulate sublethal photodamage.

Recovery from photosensitized damage using a split-dose technique was examined. Single, attached, asynchronously growing cells containing nonexchangeable HPD (12 h HPD uptake plus 9 h in porphyrin-free medium) were exposed to red light (1.2 kJ/sq m) and, after various intervals at 37°C in the dark, a second dose of 1.2 kJ/sq m. Survival rapidly increased and reached a maximum at about 9 h between light doses. Analysis of dose-response curves revealed a partial reappearance of the curve shoulder (Dq = 0.22 kJ/sq m) and a markedly reduced curve slope (D0 = 0.82 kJ/sq m) for fractionated irradiations with a 9-h interval in comparison with graded, single light exposures (Dq = 0.48 kJ/sq m; D0 = 0.41 kJ/sq m). These observations suggest that the cells developed an increased tolerance to photosensitized damage after prior HPD-light treatment. No significant change in intracellular HPD levels between irradiations was detected, indicating that the increased survival was not due to a loss of sensitizer from inside the cells. These results demonstrate that EJ cells accumulate and recover from HPD-sensitized photodamage, analogous to the accumulation and recovery from sublethal damage (Elkind recovery) in other mammalian cultures treated with ionizing radiation.

1 Supported by Grants CA-32259 and CA-29529 from the National Cancer Institute.

2 Present address: Baylor Research Foundation, Center for Advanced Laser Applications, 3600 Gaston Avenue, Barnett Tower Suite 1203, Dallas, TX 75246. To whom requests for reprints should be addressed.

Received 10/23/84. Revised 1/29/85. Accepted 2/28/85.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Seshadri, D. A. Bellnier, L. A. Vaughan, J. A. Spernyak, R. Mazurchuk, T. H. Foster, and B. W. Henderson
Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy
Clin. Cancer Res., May 1, 2008; 14(9): 2796 - 2805.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, and A. R. Oseroff
The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2
Clin. Cancer Res., April 15, 2007; 13(8): 2463 - 2470.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1985 by the American Association for Cancer Research.